Tumor Treating Fields Mesothelioma

Tumor treatment fields mesothelioma a new form of therapy, uses alternating electric field to stop the growth of cancer. It is used in conjunction with chemotherapy to treat mesothelioma of the pleural region.

The FDA approved TTFields in conjunction with pemetrexed and cisplatin in 2019 after the successful STELLAR trial. Patients may ask their doctor for this treatment.

Disrupting Cell Division

TTFields uses alternation of electrical fields that destroy cancer cell protein and prevent the cells from dividing. This prevents mesothelioma tumor cells from advancing or spreading to other organs in the body. TTFields also work to stimulate the production of proteins that destroy cancerous cells and help the immune system fight mesothelioma treatment and prognosis tumors.

During treatment patients wear the device, which is small and has insulated pads that adhere to the skin. The device is able to deliver an electrical current of low intensity, and the patient can decide how much treatment they receive. The duration of a mesothelioma advanced treatment treatment session usually lasts 30 minutes. Patients can undergo the TTFields treatment multiple times throughout the day.

A TTFields research study published in 2021 discovered that the intensity of electrical fields of 100-300 Kilohertz could stop cell division in cancer cells and cause them to die. The study included different types of cancer cells, and found that electrical fields killed all of them, regardless of the cell's structure.

The study's author recommended mixing TTFields with chemotherapy for mesothelioma. FDA approved Novocure's TTFields NovoTTF 100L in the year 2019 to treat unresectable mesothelioma of the pleural. It is now available through mesothelioma specialists in accredited medical centers in the U.S. including the West Cancer Center, mesothelioma treatment Memphis. The NovoTTF 100L device, also known as Optune Lua has been used in the treatment of mesothelioma in combination with platinum-based chemotherapy and pemetrexed. Mesothelioma patients have reported prolonged survival rate when the TTFields treatment has been combined with chemotherapy.

Another study published in "Lung Cancer", reported that TTFields therapy is effective when combined with chemotherapy. In the study researchers found that combining chemotherapy and TTFields reduced the number of malignant mesothelioma cells in animals by more than 80 percent. The study also revealed that combing these treatments boosted the production of proteins that kill mesothelioma cancerous cells and reduce the amount or cancerous DNA that is found in your body.

The TTFields treatment is a relatively new treatment, and a lot of mesothelioma physicians do not provide it for patients with pleural malignant mesothelioma. Patients still have access to this treatment through clinical trials or at mesothelioma clinics certified by Novocure.

Stalling Tumor Development

When mesothelial cancer cells multiply and outlive their normal life expectancy they develop mutated cells and may cause an overabundance that grows and expands throughout the body. The treatment of mesothelioma fields stops tumors from advancing and spreading by blocking mesothelial cells from duplicated.

The TTFields device, worn on the chest as a vest produces a series electrical fields that disrupt protein, kill cancer cells, and slow down tumor development. The device is fitted with insulated pads that stick to the skin. Patients or health care professionals can apply them at home.

Doctors suggest mixing TTFields with chemotherapy to get the best results. The combination boosts production of proteins which destroy cancerous cells, and reduces cancer cells' capacity to repair DNA damage caused by chemotherapy drugs. This makes chemotherapy drugs perform more effectively and improves the survival rate in mesothelioma sufferers.

In the STELLAR trial, which was conducted in 2017 TTFields therapy, when combined with chemotherapy significantly increased survival for mesothelioma patients. The FDA approved the NovoTTF-100L System, which is now marketed as Optune Lua, for use in conjunction with pemetrexed, carboplatin or cisplatin as the first-line treatment for unresectable malignant mesothelioma pleural in the year 2019.

Researchers have discovered that TTFields therapy is effective against mesothelioma because it interrupts cell division. The TTFields therapy causes cancer cells to split apart during a process known as mitosis. The cellular debris gets trapped in the surrounding tissues and blocks the growth new tissue. Mitosis also prevents mesothelioma cells from healing damaged DNA and makes the cells more prone to radiation therapy.

The TTFields treatment is also able to reduce blood flow to the tumor by suppressing vascular endothelial growth factor, or VEGF, and increasing hypoxia-inducible factor-1 beta, or HIF-1a, which is linked with cancer cell angiogenesis.

If you are diagnosed with mesothelioma, talk to your physician about whether TTFields is a good option for you. Novocure and mesothelioma experts are working together on clinical trials that will examine the efficacy of TTFields. Contact a Novocure certified specialist at one of the more than 1,300 U.S. Treatment Centers to find out more about the mesothelioma treatment options using TTFields.

Killing Tumor Cells

Tumor treating fields for treating tumors (TTFields), which send electrical waves throughout the body, disrupt cell division and kill tumor cells. TTFields target cancerous cells, while avoiding harming healthy cells. These electric fields also reduce DNA repair and boost cell defenses, making it harder for cancerous cells to survive. TTF is non-invasive and causes only mild side effects.

Scientists think TTFields are responsible for preventing mitosis, which is the process through which cells divide into two identical new cells. Normal cells have control mechanisms to restrict mitosis. However cancerous tumors of malignancy are able to break these restrictions and multiply at an accelerated rate. TTFields interfere with this process by blocking signals that control the mitosis of mesothelioma tumor cells. In the STELLAR study TTFields together with chemotherapy significantly improved survival rates in mesothelioma patients. Mesothelioma patients who received TTFields together with maintenance cycles of chemotherapy lasted an average of six months longer than those who only received chemotherapy.

A separate research study also found that TTFields may increase the effectiveness of certain chemotherapy drugs known as platinum-based therapies. These platinum-based treatments eliminate mesothelioma tumors by attacking mitochondria, which is the source that cancerous cells derive their energy from. When TTFields is used in conjunction with chemotherapies, the combination can result in higher levels DNA damage and faster cancer cell death.

In some instances, TTFields also increase the effects of radiation therapy. Researchers have observed that the combination of TTFields and radiation therapy may create the "synergistic" effect. This means that the combined treatment for stage 3 mesothelioma enhances the sensitivity of tumor cells to radiation.

TTFields is currently only available in specific mesothelioma centers. However, a mesothelioma expert can determine if you might be eligible for this treatment. If you're eligible, mesothelioma treatment a mesothelioma attorney can help you get access to treatment that can include TTFields in conjunction with chemotherapy. If you are a veteran mesothelioma lawyer will help you access treatment that is covered under your VA health benefits.

Side Effects

The TT fields therapy can disrupt the cancer cells by generating a field of electricity that blocks their ability to divide. This could slow down the growth of tumors, and also prevent the spread of cancer to other parts of the body. The TT Fields device is noninvasive. It does not cause any pain or damage to surrounding tissue. This is a different treatment than traditional chemotherapy which involves radiation and injections into the intravenous vein which can result in serious side effects.

In a study that included patients who received a combination of TT fields and temozolomide saw survival improvements comparable to people who were only treated with chemo. Doctors attributed the improved survival to TT fields capacity to boost the efficacy of chemotherapy and reduce the adverse effects.

Mesothelioma cancer cells can mutate and multiply in uncontrolled ways, causing the tumor to spread into your organs. Mesothelioma treatment like TT fields stops mesothelioma from reproducing and inhibiting the body's normal functions by interrupting the division of cells.

In a mesothelioma study patients who received TT fields along with chemotherapy had an average survival rate of 18.stage 2 mesothelioma treatments months. Patients who received TT fields without chemo had a median survival of 12.1 months.

Tumor-treating fields can be applied to the pleura or the thin lining that surrounds your lungs, on your abdomen or chest wall. The device is small enough to be worn for up to 18 hours each day, even in sleep. Patients are able to continue their daily lives and work while undergoing treatment.

The TT fields are a great complement with conventional chemotherapy or immunotherapy, as well as other mesothelioma treatments. Mesothelioma patient who are interested in TT should discuss the possibility with their physician. They can provide eligibility requirements and the benefits that are expected for each patient's situation.